Simplify Logo
Rapport Therapeutics

Rapport Therapeutics

Develops precision neuromedicines for brain disorders

Associate Director - Medical Writing

Full-Time
$185k - $205k/yr
Senior, Expert
Bachelor's
Boston, MA, USA
Hybrid

Three days on-site per week, Monday through Wednesday.

About the job

Requirements
  • A minimum of 8+ years of relevant medical writing experience in the biopharmaceutical industry, with proven success leading the preparation of clinical and regulatory documentation.
  • An advanced degree in a scientific or health-related discipline is preferred; an equivalent combination of education and relevant regulatory medical writing experience may be considered.
  • Experience as a lead writer for late-phase clinical programs is required; central nervous system experience is strongly preferred.
  • Thorough understanding of International Council for Harmonisation, Food and Drug Administration, and European Medicines Agency regulatory requirements for clinical and regulatory documents.
  • Demonstrated artificial intelligence literacy and practical experience using, evaluating, or implementing artificial intelligence-enabled tools, automation, structured content, content reuse, or other technologies to improve medical writing efficiency, consistency, and quality.
  • Strong judgment in the responsible use of artificial intelligence, including the ability to validate artificial intelligence-assisted outputs, identify risks and limitations, maintain data confidentiality, and ensure that final deliverables meet scientific, regulatory, and quality standards.
  • Strong written and verbal communication skills, attention to detail, and the ability to manage multiple priorities.
  • Strong stakeholder management skills, including the ability to build trust with cross-functional partners, navigate ambiguity, manage competing priorities and perspectives, resolve disputes constructively, and foster alignment among diverse contributors.
  • Demonstrated leadership, project management, stakeholder management, and mentoring skills, with the ability to influence without authority and maintain momentum in complex, cross-functional document development processes.
Responsibilities
  • Lead the development, writing, and review of key clinical and regulatory documents for the RAP-219 program, including clinical study protocols, clinical study reports, Investigator’s Brochures, briefing documents, and Module 2 summaries.
  • Collaborate with medical science, clinical operations, regulatory, biostatistics, pharmacovigilance, and other functions to ensure accurate, consistent, and strategically aligned document content; manage stakeholder input, reconcile differing perspectives, and drive timely resolution of conflicting feedback.
  • Provide strategic input and guidance on document content, structure, and timelines to support regulatory submissions and global health authority interactions.
  • Maintain up-to-date knowledge of regulatory medical writing standards, relevant regulatory guidelines, and advances in artificial intelligence, automation, structured content, and digital technologies affecting regulatory documentation.
  • Evaluate and support implementation of artificial intelligence-enabled tools and automation solutions to improve document development, quality control, content reuse, and workflow efficiency; assess benefits and limitations and help establish standards for compliant adoption.
  • Contribute to the development, modernization, and implementation of medical writing processes, templates, standards, and tools, with a focus on scalable approaches that improve quality, consistency, and operational efficiency.
Desired Qualifications
  • Central nervous system experience.
  • An advanced degree in a scientific or health-related discipline.

About the company

Rapport Therapeutics develops precision neuromedicines for neurological disorders. The company focuses on discovering and developing drugs that act only in disease-relevant areas of the brain to reduce symptoms with fewer side effects. Their discovery platform uses region-specific RAPs (Receptor Associated Proteins) to guide drug targeting to specific brain cells or regions, aiming to improve patient benefit. Unlike many peers, Rapport emphasizes selective targeting through RAPs and relies on experienced leadership to drive science and partnerships, with revenue from developing and potentially running clinical trials and related services. The goal is to provide treatments for drug-resistant epilepsies and mood disorders by delivering therapies that are active only where needed in the brain, reducing unwanted effects and improving outcomes.

Company Size

51-200

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2022

Get referred to Rapport Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 cash reached $476.8 million, funding operations into second half 2029.
  • FOCUS 1 and FOCUS 2 are enrolling, de-risking the lead epilepsy program.
  • China NMPA approved RAP-219 Phase 3, adding near-term enrollment and milestone upside.

What critics are saying

  • RAP-219 still dominates value; a Phase 3 miss in 2026 breaks the company.
  • Bipolar mania topline data lands in October 2026; failure erases the second franchise.
  • Rapport burned $111.5 million in 2025; continued execution will force dilution before commercialization.

What makes Rapport Therapeutics unique

  • RAP-219 targets TARPγ8, concentrating effect in seizure-relevant brain regions.
  • FDA allowed Phase 3 FOS initiation in Q2 2026 after Phase 2a signals.
  • Tenacia’s March 2026 China license validates RAP-219 and expands global trial execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited Paid Time Off

Commuter Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

3%

2 year growth

4%
Yahoo Finance
Jun 5th, 2026
BTIG raises Rapport Therapeutics price target to $65 on accelerated RAP-219 bipolar mania trial timeline

Rapport Therapeutics has received positive analyst coverage, with BTIG raising its price target to $65 from $53 whilst maintaining a Buy rating. The upgrade followed clinical progress on RAP-219 in bipolar mania, with Phase 2 results brought forward to Q4 from H1 2027 due to strong enrollment. Truist initiated coverage with a Buy rating and $56 price target, citing RAP-219's potential as a differentiated epilepsy treatment with best-in-category prospects for focal onset seizures. The clinical-stage biopharmaceutical company, which develops small-molecule medicines for central nervous system disorders, reported first-quarter EPS of $(0.42), beating the $(0.71) consensus estimate. CEO Abraham Ceesay highlighted strong momentum across the RAP-219 programme and upcoming milestones in epilepsy and bipolar mania trials.

Associated Press
May 7th, 2026
Rapport Therapeutics reports $476.8M cash, RAP-219 shows 90% seizure reduction in Phase 2a follow-up

Rapport Therapeutics reported first quarter 2026 financial results alongside clinical updates for its lead drug candidate RAP-219. The company posted a net loss of $19.9 million, down from $24.1 million in the prior year period, and ended the quarter with $476.8 million in cash, expected to fund operations into the second half of 2029. Follow-up data from RAP-219's Phase 2a trial in focal onset seizures showed a 90% median reduction in clinical seizures during weeks 9-12. The company's Phase 3 programme in focal onset seizures remains on track for second quarter 2026 initiation, whilst topline results from its Phase 2 bipolar mania trial are now expected in fourth quarter 2026, ahead of previous guidance. Rapport also entered a licensing agreement with Tenacia Biotechnology for RAP-219's development in Greater China.

Yahoo Finance
Apr 27th, 2026
Third Rock Ventures sells $17M stake in Rapport Therapeutics as stock climbs 230% ahead of phase 3 trials

Third Rock Ventures V, a 10% owner of Rapport Therapeutics (NASDAQ:RAPP), sold 426,005 shares on 17 April 2026 in an open-market transaction valued at approximately $17.18 million. The sale represented 5.3% of its total position in the Boston-based biotechnology company. The transaction was executed under a Rule 10b5-1 trading plan, indicating pre-scheduled selling rather than discretionary action. Following the sale, Third Rock Ventures V retains 6,709,228 shares directly and 969,218 shares indirectly, maintaining significant ownership. The sale occurred after Rapport Therapeutics' stock surged 230% over one year. The clinical-stage biopharmaceutical company develops small-molecule medicines for central nervous system disorders, with lead candidate RAP-219 in clinical trials for focal epilepsy, neuropathic pain and bipolar disorder. Rapport's market capitalisation stands at $1.33 billion.

Yahoo Finance
Mar 21st, 2026
Rapport Therapeutics licenses RAP-219 to Tenacia for $20M upfront and $308M in milestones

Rapport Therapeutics has granted Tenacia Biotechnology exclusive rights to develop and commercialise its epilepsy and bipolar candidate RAP-219 in Greater China. The deal includes a $20 million upfront payment and up to approximately $308 million in potential milestones plus tiered royalties. The agreement establishes Greater China as a major development hub for RAP-219, adding Phase 3 trial sites in China whilst Rapport retains rights elsewhere. The upfront cash provides modest relief against rising losses, which reached $111.48 million in the past year, though further capital will likely be needed. The partnership offers external validation for RAP-219 as Phase 3 epilepsy trials approach, though clinical setbacks and potential dilution remain key risks. Community fair value estimates cluster around $52 per share.

AllSci
Mar 10th, 2026
Rapport hands Tenacia China rights to epilepsy drug in USD 328m deal

Rapport hands Tenacia China rights to epilepsy drug in USD 328m deal. March 10, 2026 Boston-based Rapport Therapeutics, Inc. (Nasdaq: RAPP) and Shanghai-headquartered Tenacia Biotechnology (Hong Kong) Co., Ltd. entered a strategic collaboration granting Tenacia exclusive rights to develop and commercialize Rapport Therapeutics' RAP-219 in Greater China, covering mainland China, Hong Kong, Macau, and Taiwan. RAP-219 is a TARPγ8-specific AMPA receptor negative allosteric modulator (NAM) - a small molecule being developed for focal onset seizures (FOS), primary generalized tonic-clonic seizures, and bipolar mania. Rapport retains all rights outside the licensed territory. Deal financial terms were publicly disclosed. Under the terms of the partnership, Tenacia will pay Rapport an upfront cash payment of USD 20 million. Rapport is eligible to receive up to approximately USD 308 million in development and commercialization milestones and other payments, along with mid-single-digit to mid-teens tiered royalties on net sales in the licensed territory. Tenacia will be responsible for all RAP-219 development and commercialization activities in Greater China, including leading local clinical trial operations. No equity investment or profit-sharing arrangement was disclosed. Deal context. RAP-219 is described as a first-in-class compound that selectively modulates AMPA receptors associated with the auxiliary subunit TARPγ8. AMPA receptors mediate fast excitatory neurotransmission throughout the central nervous system, but TARPγ8 expression is concentrated in discrete brain regions - including the hippocampus and neocortex - where focal seizures commonly originate. TARPγ8 has minimal expression in the hindbrain, where AMPA receptor modulation is often associated with adverse events such as sedation and motor impairment. By selectively targeting TARPγ8-containing AMPA receptors, RAP-219 aims to suppress pathological excitatory signaling while sparing AMPA receptor activity in brain regions not implicated in seizure generation. In September 2025, Rapport reported results from a Phase IIa trial of RAP-219 in patients with drug-resistant focal onset seizures. The compound demonstrated a statistically significant reduction in long episodes - an objective electrographic biomarker correlated with clinical seizure reduction - as well as a statistically significant reduction in clinical seizures compared with baseline. Rapport has stated that two global registrational trials in focal onset seizures are planned, and in January 2026 the company announced an accelerated initiation of its Phase III program, with trials expected to begin in Q1 2026. A Phase 1 trial assessing TARPγ8 receptor occupancy in healthy adults has also been completed. Under the Tenacia collaboration, Tenacia will add Phase III clinical trial sites in China to the global registrational program with the aim of accelerating enrollment. Company background and strategic context. Rapport was founded in February 2022 and completed its IPO in 2024. The company's pipeline is built around its proprietary receptor-associated protein (RAP) technology platform, which focuses on targeting receptor-associated proteins to achieve highly selective modulation of neuronal signaling pathways. RAP-219 is the company's lead clinical-stage asset. Tenacia was founded in 2022 with backing from Bain Capital, and has developed a business model centered on in-licensing CNS therapeutics for development in Greater China. Previous Tenacia transactions include a November 2022 collaboration and supply agreement with Marinus Pharmaceuticals covering ganaxolone for Greater China, and a licensing and collaboration agreement with Praxis Precision Medicine for ulixacaltamide in Greater China. Your email address will not be published. Required fields are marked *